Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D

Colette DeJong; Dhruv S Kazi; R Adams Dudley; Randi Chen; Chien-Wen Tseng

doi:10.1001/jamacardio.2019.2223

Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D

JAMA Cardiol. 2019 Aug 1;4(8):828-830. doi: 10.1001/jamacardio.2019.2223.

Authors

Colette DeJong¹, Dhruv S Kazi², R Adams Dudley¹, Randi Chen³, Chien-Wen Tseng^{3

4}

Affiliations

¹ Center for Healthcare Value, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco.
² Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
³ Pacific Health Research and Education Institute, Honolulu, Hawaii.
⁴ Department of Family Medicine and Community Health, University of Hawaii John A. Burns School of Medicine, Honolulu.

Abstract

This study examines the insurance coverage and out-of-pocket costs to Medicare beneficiaries for the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aminobutyrates / economics*
Aminobutyrates / therapeutic use*
Angiotensin Receptor Antagonists / economics*
Angiotensin Receptor Antagonists / therapeutic use*
Biphenyl Compounds
Drug Combinations
Health Expenditures*
Heart Failure / drug therapy*
Humans
Insurance Coverage / economics*
Medicare Part D*
Tetrazoles / economics*
Tetrazoles / therapeutic use*
United States
Valsartan

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Tetrazoles
Valsartan
sacubitril and valsartan sodium hydrate drug combination